A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer

Table 2 Best Overall Response (Evaluable population, n = 64)

	Evaluable population n = 64
Complete response	5 (7.81%)
Partial response	27 (42.18%)
No change	25 (39.06%)
Progression disease	8 (12.5%)
Non evaluable*	6 (9.37%)
Objective response rate	32 (50.0%)
Disease control rate	57 (89.06%)
Median duration of the response**	Not reached

All scans of responding and/or border line stable patients were reviewed by an independent panel review.
*5 NE: (2 patients were not eligible, 3 patients had adverse events avoiding evaluation, for 1 patient, RECIST measurements were never obtained since initial CT-scan was lost).
**Median Duration of the response was not reached at the cut-off date (29/12/2009).

ISSN: 1471-2407